Clinical Trial Update: Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing a recombinant EBV vaccine for nasopharyngeal cancer patients with residual EBV DNA after standard therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infections
• Nasopharyngeal Cancer

Drugs mentioned

• recombinant Epstein-Barr virus vaccine (unknown)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Nasopharyngeal Cancer, Epstein-Barr Virus Infections | Phase 2 | Status: COMPLETED